<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37873" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ranibizumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaidyanathan</surname>
            <given-names>Uma</given-names>
          </name>
          <aff>UT Health Sci Center/McGovern Med School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Uma Vaidyanathan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37873.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy. It is in the vascular endothelial growth factor (VEGF-A) inhibitors class of medications. This activity describes the indications, action, and contraindications for ranibizumab as a valuable agent in treating ocular diseases with abnormal angiogenesis. This activity will also highlight the mechanism of action, adverse event profile, and other key factors (e.g., indications, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional professional team in the management of neovascular age-related macular degeneration, macular edema, diabetic retinopathy, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ranibizumab.</p></list-item><list-item><p>Describe the potential adverse effects of ranibizumab.</p></list-item><list-item><p>Review the appropriate monitoring necessary during ranibizumab therapy.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance ranibizumab and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37873&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37873">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37873.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ranibizumab is a humanized, recombinant monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization.<xref ref-type="bibr" rid="article-37873.r1">[1]</xref><xref ref-type="bibr" rid="article-37873.r2">[2]</xref> The vascular endothelial growth factor (VEGF) pathway has a key role in regulating angiogenesis, triggering signaling processes that promote tumor growth.<xref ref-type="bibr" rid="article-37873.r3">[3]</xref><xref ref-type="bibr" rid="article-37873.r4">[4]</xref><xref ref-type="bibr" rid="article-37873.r5">[5]</xref> Increased levels of VEGF-A are present in vitreous and aqueous fluid of patients with proliferative diabetic retinopathy, diabetic macular edema, and glaucoma.<xref ref-type="bibr" rid="article-37873.r6">[6]</xref> Additionally, VEGF pathway activation is associated with the rescue of retinal vasculature and prevents endothelial cell death in the case of hyperoxia-induced retinopathy of prematurity.<xref ref-type="bibr" rid="article-37873.r7">[7]</xref></p>
        <p>Bevacizumab is another anti-VEGF agent that preceded ranibizumab. Bevacizumab is a full-length humanized monoclonal antibody that was first FDA approved in 2004 to treat colon cancer. Due to its ability to inhibit neovascularization, bevacizumab was then used intravenously to treat neovascular age-related macular degeneration (NVAMD) as an off-label treatment.<xref ref-type="bibr" rid="article-37873.r8">[8]</xref> At the time, the thinking was that bevacizumab was unable to effectively diffuse to the choroid (although this was later proven false).<xref ref-type="bibr" rid="article-37873.r8">[8]</xref><xref ref-type="bibr" rid="article-37873.r9">[9]</xref> Therefore, researchers first developed ranibizumab as a fragment of the monoclonal antibody against VEGF-A for the treatment of NVAMD, also known as &#x0201c;wet&#x0201d; age-related macular degeneration. NVAMD consists of 10% of AMD, which is one of the leading causes of vision loss among the elderly population.<xref ref-type="bibr" rid="article-37873.r8">[8]</xref> Ranibizumab was first FDA-approved in 2006 for the treatment of NVAMD. Later, it was approved to treat the following conditions discussed below.</p>
        <p>FDA-approved indications<xref ref-type="bibr" rid="article-37873.r10">[10]</xref><xref ref-type="bibr" rid="article-37873.r11">[11]</xref><xref ref-type="bibr" rid="article-37873.r12">[12]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neovascular (wet) age-related macular degeneration (NVAMD)</p>
          </list-item>
          <list-item>
            <p>Macular edema following retinal vein occlusion (RVO)</p>
          </list-item>
          <list-item>
            <p>Myopic choroidal neovascularization (mCNV)</p>
          </list-item>
          <list-item>
            <p>Diabetic macular edema (DME)</p>
          </list-item>
          <list-item>
            <p>Diabetic retinopathy (DR) with or without DME</p>
          </list-item>
          <list-item>
            <p>Retinal ischemia</p>
          </list-item>
        </list>
        <p>In terms of a global health perspective, there is controversy regarding administering bevacizumab or ranibizumab since bevacizumab is significantly less costly. However, its use in treating NVAMD is off-label. Although both drugs have very similar effects on visual acuity in treating NVAMD, ranibizumab is more expensive than bevacizumab.<xref ref-type="bibr" rid="article-37873.r9">[9]</xref><xref ref-type="bibr" rid="article-37873.r13">[13]</xref></p>
        <p>Ranibizumab, combined with photodynamic therapy, to control abnormal growth of blood vessels in NVAMD is the gold standard in many countries; however, other treatment options with various VEGF inhibitors are also widely used.<xref ref-type="bibr" rid="article-37873.r14">[14]</xref></p>
        <p>This medication is only available by prescription from a physician.</p>
      </sec>
      <sec id="article-37873.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ranibizumab (molecular weight = 48 kD) is an affinity-matured, humanized immunoglobulin G1 monoclonal antibody fragment that&#x000a0;binds to the receptor-binding site of active VEGF-A. Thus, ranibizumab inhibits the interaction of VEGF-A with its receptors on endothelial cells, preventing endothelial proliferation, vascular permeability, and neovascularization.<xref ref-type="bibr" rid="article-37873.r15">[15]</xref> VEGF-A plays a significant role in vascular leak and angiogenesis in the development of NVAMD. Ranibizumab is an antigen-binding fragment (Fab) derived from bevacizumab and has a higher affinity to VEGF-A. Additionally, ranibizumab has one binding site for VEGF, allowing two molecules of ranibizumab to bind to one VEGF dimer. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.<xref ref-type="bibr" rid="article-37873.r2">[2]</xref><xref ref-type="bibr" rid="article-37873.r16">[16]</xref></p>
      </sec>
      <sec id="article-37873.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ranibizumab administration is by intravitreal injection.<xref ref-type="bibr" rid="article-37873.r17">[17]</xref><xref ref-type="bibr" rid="article-37873.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>For NVAMD treatment therapy, 0.5 mg (0.05 mL) is recommended as an intravitreal injection once a month.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For macular edema treatment following RVO, 0.5 mg (0.05 mL) is recommended as an intravitreal injection once a month.</p>
          </list-item>
          <list-item>
            <p>For the treatment of DME and DR, 0.3 mg (0.03 mL) is recommended as an intravitreal injection once a month.</p>
          </list-item>
          <list-item>
            <p>For the treatment of mCNV, 0.5 mg (0.5 mL) is recommended as an intravitreal injection once a month for no more than three months.</p>
          </list-item>
          <list-item>
            <p>Acute treatment administration may be with variably prescribed injection protocols.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37873.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects associated with ranibizumab use include conjunctival hemorrhage, eye pain, vitreous floaters, and a short-term and long-term increase in ocular pressure.<xref ref-type="bibr" rid="article-37873.r19">[19]</xref><xref ref-type="bibr" rid="article-37873.r20">[20]</xref><xref ref-type="bibr" rid="article-37873.r21">[21]</xref> Adverse effects of intravitreal injections include endophthalmitis (incidence reported in the range 0.019 to 1.6%), retinal detachments (incidence reported in the range 0 to 0.67%), or hemorrhage, intraocular inflammation (incidence reported in the range 1.4 to 2.9%), and risk of thromboembolic events.<xref ref-type="bibr" rid="article-37873.r15">[15]</xref><xref ref-type="bibr" rid="article-37873.r22">[22]</xref><xref ref-type="bibr" rid="article-37873.r23">[23]</xref> There are reports of a few cases of the development of significant sub-retinal hemorrhage when administering intravitreal ranibizumab.<xref ref-type="bibr" rid="article-37873.r24">[24]</xref><xref ref-type="bibr" rid="article-37873.r25">[25]</xref> The overall risk of systemic adverse effects of ranibizumab is low. However, these effects may increase in&#x000a0;patients, especially in the elderly population.<xref ref-type="bibr" rid="article-37873.r22">[22]</xref><xref ref-type="bibr" rid="article-37873.r26">[26]</xref></p>
      </sec>
      <sec id="article-37873.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications include ocular or periocular infections and hypersensitivity.<xref ref-type="bibr" rid="article-37873.r22">[22]</xref> Patients who have an ocular infection, who recently underwent ocular surgery, or have increased intraocular pressures should avoid ranibizumab use.</p>
      </sec>
      <sec id="article-37873.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>After ranibizumab administration, patient self-monitoring is essential to detect signs of infection, decreasing visual acuity and pain. Patient self-monitoring with tools such as the Amsler grid may help monitor the reactivation of NVAMD.<xref ref-type="bibr" rid="article-37873.r27">[27]</xref> Intravitreal injections can be associated with endophthalmitis, retinal detachment, and increases in intraocular pressures (IOP). The monitoring of IOPs should occur before and after the intravitreal injection of ranibizumab. Systemic exposure is low due to rapid elimination after passing through the vitreous.<xref ref-type="bibr" rid="article-37873.r28">[28]</xref> Additionally, patients with macular ischemia should be carefully monitored when considering prolonged anti-VEGF therapy due to an already compromised blood supply.<xref ref-type="bibr" rid="article-37873.r29">[29]</xref> For a 0.5 mg dose of ranibizumab, the half-life of the drug&#x000a0;is around nine days.<xref ref-type="bibr" rid="article-37873.r2">[2]</xref></p>
      </sec>
      <sec id="article-37873.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The maximum dose of ranibizumab is 0.5 mg single dose monocular, and intravitreal injection allows the drug to penetrate all retina layers, minimizing systemic effects. When cultures of endothelial cells from human organ-cultured donor corneas received treatment with varying concentrations of ranibizumab,&#x000a0;no cytotoxic effects of ranibizumab were observed.<xref ref-type="bibr" rid="article-37873.r30">[30]</xref>&#x000a0;There is no known antidote in case of an overdose of ranibizumab.</p>
      </sec>
      <sec id="article-37873.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ranibizumab is a recombinant, humanized monoclonal antibody fragment designed for intraocular use. Intravitreal injection is indicated for the treatment of neovascular age-related macular degeneration (AMD), macular edema (ME) following retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and diabetic retinopathy (DR).</p>
        <p>Proper diagnosis and management of ocular diseases can significantly impact a patient's quality of life and have long-term physical and mental health effects.</p>
        <p>Healthcare practitioners, including pharmacists, should thoroughly counsel patients so that they can make informed decisions about their treatment with ranibizumab or other VEGF inhibitors.&#x000a0;Managing the treatment of ocular diseases with abnormal angiogenesis, such as NVAMD and diabetic retinopathy, requires an interprofessional team of healthcare providers (clinicians, specialists, mid-level practitioners, nurses, and pharmacists) to ensure effective treatment and prevent and monitor adverse effects. In addition to the prescribing of physicians and medication management of pharmacists, nursing plays a crucial role in monitoring and taking/updating the patient history and reporting on therapy response and adverse events. Ranibizumab therapy requires the collaboration and communication of the entire interprofessional team to optimize therapeutic outcomes. [Level 5]</p>
        <p>Patient education and self-monitoring are crucial to detect signs of infection and a decrease in visual acuity. Intravitreal injections can be associated with endophthalmitis, retinal detachment, and increases in intraocular pressures (IOP). The intraocular pressures require monitoring before and after the intravitreal injection of ranibizumab by the ophthalmic nurse/ophthalmologist. Additionally, cost-effective treatment should be considered in the use of bevacizumab versus ranibizumab, as the outcomes of both treatments have demonstrated similar clinical results.<xref ref-type="bibr" rid="article-37873.r2">[2]</xref><xref ref-type="bibr" rid="article-37873.r9">[9]</xref><xref ref-type="bibr" rid="article-37873.r13">[13]</xref></p>
      </sec>
      <sec id="article-37873.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37873&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37873">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37873/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37873">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37873.s11">
        <title>References</title>
        <ref id="article-37873.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chong</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab for the treatment of wet AMD: a summary of real-world studies.</article-title>
            <source>Eye (Lond)</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>1526</fpage>
            <pub-id pub-id-type="pmid">27612184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2012</year>
            <volume>8</volume>
            <fpage>343</fpage>
            <page-range>343-51</page-range>
            <pub-id pub-id-type="pmid">22911433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hicklin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Feb</month>
            <day>10</day>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>1011</fpage>
            <page-range>1011-27</page-range>
            <pub-id pub-id-type="pmid">15585754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krispel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sodhi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab in diabetic macular edema.</article-title>
            <source>World J Diabetes</source>
            <year>2013</year>
            <month>Dec</month>
            <day>15</day>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>310</fpage>
            <page-range>310-8</page-range>
            <pub-id pub-id-type="pmid">24379922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Wakelee</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.</article-title>
            <source>BioDrugs</source>
            <year>2009</year>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>289</fpage>
            <page-range>289-304</page-range>
            <pub-id pub-id-type="pmid">19754219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Antiangiogenic therapy in neovascular age-related macular degeneration.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2007</year>
            <season>Winter</season>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-37</page-range>
            <pub-id pub-id-type="pmid">17237677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hemo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Itin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pe'er</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keshet</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.</article-title>
            <source>Nat Med</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>10</issue>
            <fpage>1024</fpage>
            <page-range>1024-8</page-range>
            <pub-id pub-id-type="pmid">7489357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>D'Amore</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>A brief history of anti-VEGF for the treatment of ocular angiogenesis.</article-title>
            <source>Am J Pathol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>181</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-9</page-range>
            <pub-id pub-id-type="pmid">22749677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>CATT Research Group</collab>
              <name>
                <surname>Martin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Grunwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab and bevacizumab for neovascular age-related macular degeneration.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>May</month>
            <day>19</day>
            <volume>364</volume>
            <issue>20</issue>
            <fpage>1897</fpage>
            <page-range>1897-908</page-range>
            <pub-id pub-id-type="pmid">21526923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joachim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Renner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reinhard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Theiss</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lohmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reinehr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stute</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Faissner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Protective effects on the retina after ranibizumab treatment in an ischemia model.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>e0182407</fpage>
            <pub-id pub-id-type="pmid">28800629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feiner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rundle</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Ehrlich</surname>
                <given-names>JS</given-names>
              </name>
              <collab>RISE and RIDE Research Group</collab>
            </person-group>
            <article-title>Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>119</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-801</page-range>
            <pub-id pub-id-type="pmid">22330964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evoy</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>811</fpage>
            <page-range>811-8</page-range>
            <pub-id pub-id-type="pmid">23656749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Asten</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>CTJ</given-names>
              </name>
              <name>
                <surname>Hoyng</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>van der Wilt</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Klevering</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rovers</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Grutters</surname>
                <given-names>JPC</given-names>
              </name>
            </person-group>
            <article-title>The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>e0197670</fpage>
            <pub-id pub-id-type="pmid">29772018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohamad</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mohd Isa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Ngah</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Md Bakri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ching</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hoo</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Wan Sulaiman</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.</article-title>
            <source>Int J Ophthalmol</source>
            <year>2017</year>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1889</fpage>
            <page-range>1889-1897</page-range>
            <pub-id pub-id-type="pmid">29259909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blick</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Wagstaff</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab.</article-title>
            <source>Drugs</source>
            <year>2007</year>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>1199</fpage>
            <page-range>1199-206; discussion 1207-9</page-range>
            <pub-id pub-id-type="pmid">17521219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Rafique</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosconi</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pyles</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wiegand</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.</article-title>
            <source>Angiogenesis</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-85</page-range>
            <pub-id pub-id-type="pmid">22302382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Francom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Grzeschik</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>7</issue>
            <fpage>667</fpage>
            <page-range>667-675</page-range>
            <pub-id pub-id-type="pmid">31047375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-47</page-range>
            <pub-id pub-id-type="pmid">28324452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Almukhtar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bhorade</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Melia</surname>
                <given-names>M</given-names>
              </name>
              <collab>Diabetic Retinopathy Clinical Research Network Investigators</collab>
            </person-group>
            <article-title>Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2015</year>
            <month>May</month>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>589</fpage>
            <page-range>589-97</page-range>
            <pub-id pub-id-type="pmid">25719991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>e109744</fpage>
            <pub-id pub-id-type="pmid">25330364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kampougeris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mitropoulou</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations.</article-title>
            <source>J Curr Glaucoma Pract</source>
            <year>2013</year>
            <season>Jan-Apr</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-24</page-range>
            <pub-id pub-id-type="pmid">26997776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falavarjani</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
            </person-group>
            <article-title>Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.</article-title>
            <source>Eye (Lond)</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>787</fpage>
            <page-range>787-94</page-range>
            <pub-id pub-id-type="pmid">23722722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fintak</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Blinder</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Regillo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hollands</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.</article-title>
            <source>Retina</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1395</fpage>
            <page-range>1395-9</page-range>
            <pub-id pub-id-type="pmid">18827737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karagiannis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Mitropoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ladas</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab.</article-title>
            <source>Ophthalmologica</source>
            <year>2009</year>
            <volume>223</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-82</page-range>
            <pub-id pub-id-type="pmid">19390227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modarres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naseripour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Falavarjani</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Nikeghbali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hashemi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parvaresh</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD.</article-title>
            <source>Retina</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>319</fpage>
            <page-range>319-24</page-range>
            <pub-id pub-id-type="pmid">19287288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>CMG</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?</article-title>
            <source>Am J Ophthalmol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>152</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-331</page-range>
            <pub-id pub-id-type="pmid">21855670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gillies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheidow</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Souied</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>MS</given-names>
              </name>
              <collab>LUMINOUS Steering Committee</collab>
            </person-group>
            <article-title>Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>1161</fpage>
            <page-range>1161-7</page-range>
            <pub-id pub-id-type="pmid">23850682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tuomi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jumbe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eppler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuebler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Damico-Beyer</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2013</year>
            <month>Mar</month>
            <day>05</day>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>1616</fpage>
            <page-range>1616-24</page-range>
            <pub-id pub-id-type="pmid">23361508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manousaridis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Talks</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?</article-title>
            <source>Br J Ophthalmol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-84</page-range>
            <pub-id pub-id-type="pmid">22250209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37873.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merz</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>R&#x000f6;ckel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ballikaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Auffarth</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Schmack</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Effects of ranibizumab (Lucentis&#x000ae;) and bevacizumab (Avastin&#x000ae;) on human corneal endothelial cells.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>316</fpage>
            <pub-id pub-id-type="pmid">30537942</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
